// App-Quantinova.ai

1035 : Final results of a phase 2 study of ramucirumab (RAM) plus eribulin (E) versus E in advanced metastatic breast cancer (MBC).

Researchers

Presenter

  • Denise A. Yardley

Principal Investigators

  • Paul D. Richards

  • James Andrew Reeves

  • Hatem Hussein Soliman

  • Devchand Paul

  • Foluso Olabisi Ademuyiwa

  • Troy H. Guthrie

  • Jane L. Bromund

  • Yihuan Xu

Medical Centers

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX

  • Oncology and Hematology Associates of Southwest Virginia, Salem, VA

  • Baptist Cancer Institute, Jacksonville, FL

  • Washington University School of Medicine in St. Louis, St. Louis, MOEli Lilly and Company, Indianapolis, INImClone Systems Corporation, a wholly owned subsidiary of Eli Lilly and Company, Bridgewater, NJ

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC

  • Rocky Mountain Cancer Center, Denver, CO

  • ImClone Systems, a wholly-owned subsidiary of Eli Lilly &Co, Bridgewater, NJ

  • Florida Cancer Specialists, Fort Myers, FL

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Brain metastasis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Ramucirumab

  • Eribulin

  • taxane

Outcome

  • Negative

Study Design

  • randomized

Phase

  • II

Study Id's

  • NCT01427933

Sponsors

  • Eli Lilly and Company

  • Eli Lilly and Company

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved